Eterna Therapeutics Stock EBITDA
| ERNA Stock | USD 0.52 0.01 1.89% |
Eterna Therapeutics fundamentals help investors to digest information that contributes to Eterna Therapeutics' financial success or failures. It also enables traders to predict the movement of Eterna Stock. The fundamental analysis module provides a way to measure Eterna Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eterna Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -19.9 M | -18.9 M |
Eterna | EBITDA |
Eterna Therapeutics Company EBITDA Analysis
Eterna Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Eterna Therapeutics EBITDA | (19.93 M) |
Most of Eterna Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eterna Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Eterna EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Eterna Therapeutics is extremely important. It helps to project a fair market value of Eterna Stock properly, considering its historical fundamentals such as EBITDA. Since Eterna Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eterna Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eterna Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Eterna Ebitda
Ebitda |
|
According to the company disclosure, Eterna Therapeutics reported earnings before interest,tax, depreciation and amortization of (19.93 Million). This is 102.27% lower than that of the Biotechnology sector and 119.9% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.51% higher than that of the company.
Eterna EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eterna Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eterna Therapeutics could also be used in its relative valuation, which is a method of valuing Eterna Therapeutics by comparing valuation metrics of similar companies.Eterna Therapeutics is currently under evaluation in ebitda category among its peers.
Eterna Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Eterna Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Eterna Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Eterna Therapeutics' value.| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 100.0 | Activest Wealth Management | 2024-06-30 | 50.0 | Bank Of America Corp | 2024-06-30 | 29.0 | Royal Bank Of Canada | 2024-06-30 | 22.0 | Group One Trading, Lp | 2024-06-30 | 19.0 | Citigroup Inc | 2024-09-30 | 15.0 | Jpmorgan Chase & Co | 2024-06-30 | 14.0 | Aspire Private Capital, Llc | 2024-09-30 | 10.0 | Qube Research & Technologies | 2024-06-30 | 4.0 | Cypress Point Wealth Management, Llc | 2024-09-30 | 94.4 K | Naviter Wealth, Llc | 2024-09-30 | 78.8 K |
Eterna Fundamentals
| Return On Equity | -11.54 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (104.91) % | ||||
| Current Valuation | 56 M | ||||
| Shares Outstanding | 51.37 M | ||||
| Shares Owned By Institutions | 10.99 % | ||||
| Number Of Shares Shorted | 44.46 K | ||||
| Price To Book | 2.10 X | ||||
| Price To Sales | 164.91 X | ||||
| Revenue | 68 K | ||||
| EBITDA | (19.93 M) | ||||
| Net Income | (21.67 M) | ||||
| Cash And Equivalents | 19.41 M | ||||
| Cash Per Share | 6.60 X | ||||
| Total Debt | 41.84 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.08 X | ||||
| Book Value Per Share | 0.41 X | ||||
| Cash Flow From Operations | (20.41 M) | ||||
| Short Ratio | 1.07 X | ||||
| Earnings Per Share | (8.31) X | ||||
| Price To Earnings To Growth | (0.03) X | ||||
| Target Price | 3.0 | ||||
| Beta | 7.77 | ||||
| Market Capitalization | 26.71 M | ||||
| Total Asset | 49.13 M | ||||
| Retained Earnings | (186.98 M) | ||||
| Working Capital | 3.03 M | ||||
| Net Asset | 49.13 M |
About Eterna Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eterna Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eterna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eterna Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:Check out Eterna Therapeutics Piotroski F Score and Eterna Therapeutics Altman Z Score analysis. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.31) | Revenue Per Share 0.03 | Return On Assets (0.29) | Return On Equity (11.54) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.